Literature DB >> 21051744

Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients.

Paola Fioretto1, Behzad Najafian, David E R Sutherland, Michael Mauer.   

Abstract

BACKGROUND AND OBJECTIVES: Calcineurin inhibitors, while representing advances for solid organ transplantation, have nephrotoxic potential that reduces their net benefit. Tacrolimus has been considered less nephrotoxic than cyclosporine, but direct quantitative comparisons of the changes in renal structure from baseline to follow-up biopsies have not been done. To avoid the pitfalls of renal allograft studies, including rejection and disease recurrence, we compared the development of calcineurin lesions in the native kidneys of 14 tacrolimus- and 12 calcineurin-treated pancreas transplant alone recipients cured of type 1 diabetes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Research renal biopsies obtained before and at 5 years after transplantation were studied using established morphometric methods.
RESULTS: The cyclosporine and tacrolimus groups had, respectively, on average, 33% versus 44% decline in GFR (ns), 27% versus 29% increase in cortical interstitial fractional volume (ns), 245% versus 347% increase in the fractional volume of cortical tubules that were atrophic (ns), and 291% versus 392% increase in the percent of globally sclerotic glomeruli (ns). Arteriolar hyalinosis did not change significantly in either group.
CONCLUSIONS: These studies indicate that the nephrotoxic potential of tacrolimus and cyclosporine are equivalent and support the development of strategies to reduce these negative effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051744      PMCID: PMC3022230          DOI: 10.2215/CJN.03850510

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  28 in total

Review 1.  Calcineurin. Structure, function, and inhibition.

Authors:  C S Hemenway; J Heitman
Journal:  Cell Biochem Biophys       Date:  1999       Impact factor: 2.194

Review 2.  Calcineurin nephrotoxicity.

Authors:  David Williams; Lukas Haragsim
Journal:  Adv Chronic Kidney Dis       Date:  2006-01       Impact factor: 3.620

3.  Renal histopathological lesions after orthotopic liver transplantation (OLT).

Authors:  Evangeline Pillebout; Dominique Nochy; Gary Hill; Filomena Conti; Corinne Antoine; Yvon Calmus; Denis Glotz
Journal:  Am J Transplant       Date:  2005-05       Impact factor: 8.086

Review 4.  The mechanism of action of cyclosporin A and FK506.

Authors:  S Ho; N Clipstone; L Timmermann; J Northrop; I Graef; D Fiorentino; J Nourse; G R Crabtree
Journal:  Clin Immunol Immunopathol       Date:  1996-09

Review 5.  FK506 nephrotoxicity.

Authors:  W F Finn
Journal:  Ren Fail       Date:  1999 May-Jul       Impact factor: 2.606

6.  A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.

Authors:  J D Pirsch; J Miller; M H Deierhoi; F Vincenti; R S Filo
Journal:  Transplantation       Date:  1997-04-15       Impact factor: 4.939

7.  Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group.

Authors:  K Solez; F Vincenti; R S Filo
Journal:  Transplantation       Date:  1998-12-27       Impact factor: 4.939

8.  Reversal of lesions of diabetic nephropathy after pancreas transplantation.

Authors:  P Fioretto; M W Steffes; D E Sutherland; F C Goetz; M Mauer
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

9.  Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506.

Authors:  K P Platz; A R Mueller; G Blumhardt; S Bachmann; W O Bechstein; A Kahl; P Neuhaus
Journal:  Transplantation       Date:  1994-07-27       Impact factor: 4.939

10.  Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients.

Authors:  P Fioretto; M W Steffes; M J Mihatsch; E H Strøm; D E Sutherland; M Mauer
Journal:  Kidney Int       Date:  1995-08       Impact factor: 10.612

View more
  6 in total

Review 1.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

2.  Results of pancreas transplantation alone with special attention to native kidney function and proteinuria in type 1 diabetes patients.

Authors:  Ugo Boggi; Fabio Vistoli; Gabriella Amorese; Rosa Giannarelli; Alberto Coppelli; Rita Mariotti; Lorenzo Rondinini; Massimiliamo Barsotti; Alberto Piaggesi; Anna Tedeschi; Stefano Signori; Nelide De Lio; Margherita Occhipinti; Emanuela Mangione; Diego Cantarovich; Stefano Del Prato; Franco Mosca; Piero Marchetti
Journal:  Rev Diabet Stud       Date:  2011-08-10

Review 3.  The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient.

Authors:  Beje Thomas; Matthew R Weir
Journal:  Curr Cardiol Rep       Date:  2015-11       Impact factor: 2.931

4.  Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes.

Authors:  Mark E Molitch; Amanda I Adler; Allan Flyvbjerg; Robert G Nelson; Wing-Yee So; Christoph Wanner; Bertram L Kasiske; David C Wheeler; Dick de Zeeuw; Carl E Mogensen
Journal:  Kidney Int       Date:  2014-04-30       Impact factor: 10.612

Review 5.  Metabolic syndrome in children with chronic kidney disease and after renal transplantation.

Authors:  Mieczysław Litwin; Anna Niemirska
Journal:  Pediatr Nephrol       Date:  2013-06-13       Impact factor: 3.714

6.  Renal Complications of Hematopoietic Stem Cell Transplantation: Report of a Case and Review of the Literature.

Authors:  E Liquete; S R Williamson; N Janakiraman; K K Venkat
Journal:  Indian J Nephrol       Date:  2017 Nov-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.